Glioblastoma with oligodendroglioma component (GBM-O)

Molecular genetic and clinical characteristics

Christina L. Appin, Jingjing Gao, Candace Chisolm, Mike Torian, Dianne Alexis, Cristina Vincentelli, Matthew J. Schniederjan, Costas Hadjipanayis, Jeffrey J. Olson, Stephen Hunter, Chunhai Hao, Daniel J. Brat

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Glioblastoma (GBM) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM-O), was designated by the World Health Organization (WHO) in 2007. We investigated GBM-Os for their clinical and molecular characteristics as compared to other forms of GBM. Tissue samples were used to determine EGFR, PTEN, and 1p and 19q status by fluorescence in situ hybridization (FISH); p53 and mutant IDH1 protein expression by immunohistochemistry (IHC); and MGMT promoter status by methylation-specific polymerase chain reaction (PCR). GBM-Os accounted for 11.9% of all GBMs. GBM-Os arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM-Os compared to those with other GBMs, with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM-O appeared to be associated with a younger age at presentation. Among patients with GBM-O, younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM-O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.

Original languageEnglish (US)
Pages (from-to)454-461
Number of pages8
JournalBrain Pathology
Volume23
Issue number4
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Oligodendroglioma
Glioblastoma
Molecular Biology
Survival
Mutation Rate
Mutant Proteins
Fluorescence In Situ Hybridization
Brain Neoplasms
Methylation
Immunohistochemistry

Keywords

  • glioblastoma
  • glioblastoma with oligodendroglioma component
  • IDH1 mutation
  • LOH 1p 19q
  • molecular characteristics

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Appin, C. L., Gao, J., Chisolm, C., Torian, M., Alexis, D., Vincentelli, C., ... Brat, D. J. (2013). Glioblastoma with oligodendroglioma component (GBM-O): Molecular genetic and clinical characteristics. Brain Pathology, 23(4), 454-461. https://doi.org/10.1111/bpa.12018

Glioblastoma with oligodendroglioma component (GBM-O) : Molecular genetic and clinical characteristics. / Appin, Christina L.; Gao, Jingjing; Chisolm, Candace; Torian, Mike; Alexis, Dianne; Vincentelli, Cristina; Schniederjan, Matthew J.; Hadjipanayis, Costas; Olson, Jeffrey J.; Hunter, Stephen; Hao, Chunhai; Brat, Daniel J.

In: Brain Pathology, Vol. 23, No. 4, 01.07.2013, p. 454-461.

Research output: Contribution to journalArticle

Appin, CL, Gao, J, Chisolm, C, Torian, M, Alexis, D, Vincentelli, C, Schniederjan, MJ, Hadjipanayis, C, Olson, JJ, Hunter, S, Hao, C & Brat, DJ 2013, 'Glioblastoma with oligodendroglioma component (GBM-O): Molecular genetic and clinical characteristics', Brain Pathology, vol. 23, no. 4, pp. 454-461. https://doi.org/10.1111/bpa.12018
Appin, Christina L. ; Gao, Jingjing ; Chisolm, Candace ; Torian, Mike ; Alexis, Dianne ; Vincentelli, Cristina ; Schniederjan, Matthew J. ; Hadjipanayis, Costas ; Olson, Jeffrey J. ; Hunter, Stephen ; Hao, Chunhai ; Brat, Daniel J. / Glioblastoma with oligodendroglioma component (GBM-O) : Molecular genetic and clinical characteristics. In: Brain Pathology. 2013 ; Vol. 23, No. 4. pp. 454-461.
@article{5736d74abf194acca15bc46223455cc4,
title = "Glioblastoma with oligodendroglioma component (GBM-O): Molecular genetic and clinical characteristics",
abstract = "Glioblastoma (GBM) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM-O), was designated by the World Health Organization (WHO) in 2007. We investigated GBM-Os for their clinical and molecular characteristics as compared to other forms of GBM. Tissue samples were used to determine EGFR, PTEN, and 1p and 19q status by fluorescence in situ hybridization (FISH); p53 and mutant IDH1 protein expression by immunohistochemistry (IHC); and MGMT promoter status by methylation-specific polymerase chain reaction (PCR). GBM-Os accounted for 11.9{\%} of all GBMs. GBM-Os arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM-Os compared to those with other GBMs, with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM-O appeared to be associated with a younger age at presentation. Among patients with GBM-O, younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM-O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.",
keywords = "glioblastoma, glioblastoma with oligodendroglioma component, IDH1 mutation, LOH 1p 19q, molecular characteristics",
author = "Appin, {Christina L.} and Jingjing Gao and Candace Chisolm and Mike Torian and Dianne Alexis and Cristina Vincentelli and Schniederjan, {Matthew J.} and Costas Hadjipanayis and Olson, {Jeffrey J.} and Stephen Hunter and Chunhai Hao and Brat, {Daniel J.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1111/bpa.12018",
language = "English (US)",
volume = "23",
pages = "454--461",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Glioblastoma with oligodendroglioma component (GBM-O)

T2 - Molecular genetic and clinical characteristics

AU - Appin, Christina L.

AU - Gao, Jingjing

AU - Chisolm, Candace

AU - Torian, Mike

AU - Alexis, Dianne

AU - Vincentelli, Cristina

AU - Schniederjan, Matthew J.

AU - Hadjipanayis, Costas

AU - Olson, Jeffrey J.

AU - Hunter, Stephen

AU - Hao, Chunhai

AU - Brat, Daniel J.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Glioblastoma (GBM) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM-O), was designated by the World Health Organization (WHO) in 2007. We investigated GBM-Os for their clinical and molecular characteristics as compared to other forms of GBM. Tissue samples were used to determine EGFR, PTEN, and 1p and 19q status by fluorescence in situ hybridization (FISH); p53 and mutant IDH1 protein expression by immunohistochemistry (IHC); and MGMT promoter status by methylation-specific polymerase chain reaction (PCR). GBM-Os accounted for 11.9% of all GBMs. GBM-Os arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM-Os compared to those with other GBMs, with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM-O appeared to be associated with a younger age at presentation. Among patients with GBM-O, younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM-O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.

AB - Glioblastoma (GBM) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM-O), was designated by the World Health Organization (WHO) in 2007. We investigated GBM-Os for their clinical and molecular characteristics as compared to other forms of GBM. Tissue samples were used to determine EGFR, PTEN, and 1p and 19q status by fluorescence in situ hybridization (FISH); p53 and mutant IDH1 protein expression by immunohistochemistry (IHC); and MGMT promoter status by methylation-specific polymerase chain reaction (PCR). GBM-Os accounted for 11.9% of all GBMs. GBM-Os arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM-Os compared to those with other GBMs, with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM-O appeared to be associated with a younger age at presentation. Among patients with GBM-O, younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM-O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.

KW - glioblastoma

KW - glioblastoma with oligodendroglioma component

KW - IDH1 mutation

KW - LOH 1p 19q

KW - molecular characteristics

UR - http://www.scopus.com/inward/record.url?scp=84879225414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879225414&partnerID=8YFLogxK

U2 - 10.1111/bpa.12018

DO - 10.1111/bpa.12018

M3 - Article

VL - 23

SP - 454

EP - 461

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 4

ER -